doi: 10.1002/adma.202507526 367 WangZWuSZhuCShenJ
GLP-1 receptor agonists and changes in eating behaviors and eating disorder risk: a rapid review
On May 22, Eli Lilly formally submitted an application for a randomized, double-blind, phase 3 clinical study of the GIP/GLP-1/Glucagon triple agonist Retatrutide (LY3437943)
Despite these encouraging findings, several challenges must be addressed before EA can be widely recommended in clinical practice
The His 7 substitution by Ala resulted in a 111- to 374-fold reduction in affinity in these two studies, in contrast with only a 10-fold reduction at recombinant human GLP-1R (hGLP-1R) caused by replacing His 7 by Tyr (Xiao et al ., 2001)
Unlike conventional formulations, the liposomal structure surrounds glutathione with phospholipids, helping maintain its integrity as it passes through the digestive system